| Literature DB >> 27696333 |
Liang Dong1,2, Yong Zhou1, Zhao-Qiong Zhu2, Tian Liu1, Jia-Xi Duan1, Jun Zhang3, Ping Li1, Bruce D Hammcok4, Cha-Xiang Guan5.
Abstract
Triggering receptors expressed on myeloid cell-1 (TREM-1) is a superimmunoglobulin receptor expressed on myeloid cells. TREM-1 amplifies the inflammatory response. Epoxyeicosatrienoic acids (EETs), the metabolites of arachidonic acid derived from the cytochrome P450 enzyme, have anti-inflammatory properties. However, the effects of EETs on TREM-1 expression under inflammatory stimulation remain unclear. Therefore, inhibition of soluble epoxide hydrolase (sEH) with a highly selective inhibitor [1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea, TPPU] was used to stabilize EETs. LPS was intratracheally injected into mice to induce pulmonary inflammation, after TPPU treatment for 3 h. Histological examination showed TPPU treatment-alleviated LPS-induced pulmonary inflammation. TPPU decreased TREM-1 expression, but not DAP12 or MyD88 expression. Murine peritoneal macrophages were challenged with LPS in vitro. We found that TPPU reduced LPS-induced TREM-1 expression in a dose-dependent manner, but not DAP12 or MyD88 expression. TPPU also decreased downstream signal from TREM-1, reducing pro-inflammatory cytokine TNF-α and IL-1β mRNA expression. Furthermore, TPPU treatment inhibited IkB degradation in vivo and in vitro. Our results indicate that the inhibition of sEH suppresses LPS-induced TREM-1 expression and inflammation via inhibiting NF-kB activation in murine macrophage.Entities:
Keywords: epoxyeicosatrienoic acids; inflammation; macrophage; soluble epoxide hydrolase inhibitor; triggering receptor expressed on myeloid cells-1
Mesh:
Substances:
Year: 2017 PMID: 27696333 DOI: 10.1007/s10753-016-0448-6
Source DB: PubMed Journal: Inflammation ISSN: 0360-3997 Impact factor: 4.092